IND https://www.bioworld.com/rss en-us FDA clears IND for Naturecell’s Astrostem-AU for autism http://www.bioworld.com/articles/730431 Thu, 16 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730431-fda-clears-ind-for-naturecells-astrostem-au-for-autism Brain clay model ‘Immune reset’ is ambition of Tr1x’s allogenic Tr1 cell therapy BioWorld. “The goal is to reset the immune system rather than continuously suppress it, and we believe we have a unique technology to do that.”]]> http://www.bioworld.com/articles/730296 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730296-immune-reset-is-ambition-of-tr1xs-allogenic-tr1-cell-therapy Cell therapy illustration Canwell gains IND clearance for ADC CAN-016 http://www.bioworld.com/articles/730166 Tue, 07 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730166-canwell-gains-ind-clearance-for-adc-can-016 Illustration of magnifying glass and antibodies Telomir Pharmaceuticals submits IND in U.S. for Telomir-1 in TNBC http://www.bioworld.com/articles/730058 Wed, 01 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730058-telomir-pharmaceuticals-submits-ind-in-us-for-telomir-1-in-tnbc Illustration of dividing breast cancer cell Otsuka to acquire PTSD drugmaker Transcend in $1.2B deal http://www.bioworld.com/articles/730090 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/730090-otsuka-to-acquire-ptsd-drugmaker-transcend-in-12b-deal Brain with handshake and cityscape Aktis Oncology’s AKY-2519 gains IND approvals http://www.bioworld.com/articles/730037 Tue, 31 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730037-aktis-oncologys-aky-2519-gains-ind-approvals 3D rendering conceptualizing theranostics Otsuka to acquire PTSD drugmaker Transcend in $1.2B deal http://www.bioworld.com/articles/729952 Mon, 30 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729952-otsuka-to-acquire-ptsd-drugmaker-transcend-in-12b-deal Brain with handshake and cityscape Endocyclic’s ENDO-205 gains IND clearance for endometriosis http://www.bioworld.com/articles/729860 Tue, 24 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729860-endocyclics-endo-205-gains-ind-clearance-for-endometriosis Innorna’s IN-026 gains IND clearance for refractory gout http://www.bioworld.com/articles/729689 Wed, 18 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729689-innornas-in-026-gains-ind-clearance-for-refractory-gout Unixell Biotech’s UX-GIP001 gains IND clearance for epilepsy http://www.bioworld.com/articles/729645 Mon, 16 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729645-unixell-biotechs-ux-gip001-gains-ind-clearance-for-epilepsy Brain and encephalography Rapport’s RAP-219 gets more phase III funding with Tenacia deal http://www.bioworld.com/articles/729456 Tue, 10 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729456-rapports-rap-219-gets-more-phase-iii-funding-with-tenacia-deal Brain with handshake and cityscape FDA clears IND for epigenetic immunoactivator http://www.bioworld.com/articles/729392 Fri, 06 Mar 2026 08:00:00 -0500 https://www.bioworld.com/articles/729392-fda-clears-ind-for-epigenetic-immunoactivator 3D Rendering of tumor microenvironment Kestrel’s KST-6051 gains IND clearance for KRAS-driven cancers http://www.bioworld.com/articles/729389 Fri, 06 Mar 2026 08:00:00 -0500 https://www.bioworld.com/articles/729389-kestrels-kst-6051-gains-ind-clearance-for-kras-driven-cancers Lung cancer driven by the Kras oncogene shown in purple Mutated KRAS-driven lung cancer cells (purple) in a genetically engineered mouse model of lung cancer. Credit: Eric Snyder, Huntsman Cancer Institute at the University of Utah/National Cancer Institute, NIH UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE http://www.bioworld.com/articles/729298 Wed, 04 Mar 2026 12:00:00 -0500 https://www.bioworld.com/articles/729298-ucb-inks-11b-deal-for-antengenes-autoimmune-bispecific-tce Red and blue bispecific antibodies Systimmune’s iza-bren hits phase III breast cancer goals in China http://www.bioworld.com/articles/729321 Tue, 03 Mar 2026 12:00:00 -0500 https://www.bioworld.com/articles/729321-systimmunes-iza-bren-hits-phase-iii-breast-cancer-goals-in-china Cancer tumor in breast illustration Sanaregen Vision’s SVT-001 cleared for clinic for familial drusen http://www.bioworld.com/articles/729151 Tue, 03 Mar 2026 08:00:00 -0500 https://www.bioworld.com/articles/729151-sanaregen-visions-svt-001-cleared-for-clinic-for-familial-drusen Medical vector illustration showing cross section of an eyeball with close up of the macula Systimmune’s iza-bren hits phase III breast cancer goals in China http://www.bioworld.com/articles/729258 Fri, 27 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/729258-systimmunes-iza-bren-hits-phase-iii-breast-cancer-goals-in-china Cancer tumor in breast illustration FDA approves CSPC’s IND for SYH-2082 for weight management http://www.bioworld.com/articles/728886 Mon, 16 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728886-fda-approves-cspcs-ind-for-syh-2082-for-weight-management Viking to push oral GLP-1/GIP drug into phase III obesity trial http://www.bioworld.com/articles/728847 Thu, 12 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728847-viking-to-push-oral-glp-1-gip-drug-into-phase-iii-obesity-trial Pills and bottle Precision Biosciences’ PBGENE-DMD cleared to enter clinic http://www.bioworld.com/articles/728787 Wed, 11 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728787-precision-biosciences-pbgene-dmd-cleared-to-enter-clinic Illustration of DNA composing the human body FDA clearance for Nextpoint’s IND for T-cell engager NPX-372 http://www.bioworld.com/articles/728767 Tue, 10 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728767-fda-clearance-for-nextpoints-ind-for-t-cell-engager-npx-372 Illustration of T cells attacking tumor FDA clears IND for Affinia’s AFTX-201 for BAG3-DCM http://www.bioworld.com/articles/728631 Thu, 05 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728631-fda-clears-ind-for-affinias-aftx-201-for-bag3-dcm Heart scientific overlay Prelude’s JAK2 V617F inhibitor PRT-12396 gains IND clearance http://www.bioworld.com/articles/728601 Wed, 04 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728601-preludes-jak2-v617f-inhibitor-prt-12396-gains-ind-clearance 3D illustration showing cross section of a human bone ABL Bio files IND application for ABL-209 http://www.bioworld.com/articles/728509 Tue, 03 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728509-abl-bio-files-ind-application-for-abl-209 Antibodies attacking cancer cell Onchilles Pharma’s N-17350 gains IND clearance for solid tumors http://www.bioworld.com/articles/728508 Tue, 03 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728508-onchilles-pharmas-n-17350-gains-ind-clearance-for-solid-tumors Illustration of cancer tumor IND approval for Trace Biosciences’ nerve imaging agent http://www.bioworld.com/articles/728454 Mon, 02 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728454-ind-approval-for-trace-biosciences-nerve-imaging-agent Neural network Eikon Therapeutics seeks up to $317M raise in Nasdaq IPO http://www.bioworld.com/articles/728477 Thu, 29 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/728477-eikon-therapeutics-seeks-up-to-317m-raise-in-nasdaq-ipo Going public ticker Life Biosciences’ ER-100 cleared for clinic in optic neuropathies http://www.bioworld.com/articles/728416 Thu, 29 Jan 2026 08:00:00 -0500 https://www.bioworld.com/articles/728416-life-biosciences-er-100-cleared-for-clinic-in-optic-neuropathies Illustration of the optic nerve connecting eye to brain Siren Biotechnology’s glioma program gains IND clearance http://www.bioworld.com/articles/728413 Thu, 29 Jan 2026 08:00:00 -0500 https://www.bioworld.com/articles/728413-siren-biotechnologys-glioma-program-gains-ind-clearance DNA and cancer cells 1st Biotherapeutics closes $22M series D, preps for IPO http://www.bioworld.com/articles/728499 Tue, 27 Jan 2026 00:00:00 -0500 https://www.bioworld.com/articles/728499-1st-biotherapeutics-closes-22m-series-d-preps-for-ipo Korean Won currency symbol made of gray cast iron